Pharmaceutical companies and medical device manufacturers are anticipating a significant impact from artificial intelligence (AI) on their businesses. A survey of some 120 executives conducted by the Deloitte Center for Health Solutions revealed that these companies are already experimenting with AI and expect it to revolutionize drug development, supply chains, compliance, and regulatory affairs. The survey also highlighted the governance and oversight structures being established to manage AI implementation, with a focus on research and product discovery. The article explores the potential of AI in the pharmaceutical and medical device industries, as well as the challenges and opportunities it presents.
How will artificial intelligence revolutionize drug development and supply chains in the pharmaceutical and medical device industries?
Share your opinion in the comments below..
